-
Janssen v. Teva: Federal Circuit Affirms Validity of Paliperidone Palmitate Dosing Regimen Patent
In a significant ruling for pharmaceutical patent litigation, the Federal Circuit in Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., Nos. 25-1228, 25-1252 (Fed. Cir. July 8, 2025),…
4 min read
-
Egenera, Inc. v. Cisco Systems, Inc.: Federal Circuit Affirms Noninfringement Verdict on All Asserted Claims
In a resounding victory for Cisco Systems, the Federal Circuit affirmed a district court’s ruling that Cisco’s Unified Computing System (“UCS”) does not infringe U.S. Patent No. 7,231,430,…
4 min read
-
Eye Therapies, LLC v. Slayback Pharma, LLC: “Consisting Essentially Of” Precludes Other Active Ingredients
In a significant reversal for the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB), in Eye Therapies, LLC v. Slayback Pharma, LLC the Federal Circuit…
4 min read
-
Realtek Semiconductor Corp. v. ITC: Federal Circuit Declines Jurisdiction Over Sanctions Appeal
In Realtek Semiconductor Corporation v. International Trade Commission, No. 23-1187 (Fed. Cir. June 18, 2025), the Federal Circuit dismissed Realtek’s appeal for lack of jurisdiction, holding that a…
4 min read
-
Optis Cellular Technology v. Apple Inc.: Federal Circuit Orders New Trial on Infringement and Damages Due to Unanimity Violation and Improper Evidence
The Federal Circuit’s June 16, 2025, decision in Optis Cellular Technology, LLC v. Apple Inc., Nos. 2022-1904, 2022-1925, vacates a $300 million damages judgment in a high-stakes standard-essential…
4 min read
-
Ancora Technologies, Inc. v. Roku, Inc.: Federal Circuit Vacates PTAB Decision on Licensing Nexus in Obviousness Analysis
In the June 16, 2025 decision of Ancora Technologies, Inc. v. Roku, Inc., the Federal Circuit vacated and remanded two inter partes review (IPR) decisions by the Patent…
4 min read
